We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A Senate report released Sunday heightened scrutiny of a pricing and prescribing strategy used by Kaleo to hike the price of its opioid overdose reversal autoinjector more than 600% in less than three years.